Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet.

Authors: JF Guest, JJ Bai, RR Taylor, E Sladkevicius, PJ Lee, RH Lachmann
Source: Journal of Intellectual Disability Research 2013; 57(6):567-79.

ABSTRACT

Background: To quantify the costs and consequences of managing phenylketonuria (PKU) in the UK and to estimate the potential implications to the UK’s National Health Service (NHS) of keeping patients on a phenylalanine-restricted diet for life.

Methods: A computer-based model was constructed depicting the management of PKU patients over the first 36 years of their life, derived from patients suffering from this metabolic disorder in The Health Improvement Network (THIN) Database (a nationally representative database of patients registered with general practitioners (GPs) in the UK). The model was used to estimate the incidence of co-morbidities and the levels of healthcare resource use and corresponding costs over the 36 years.

Results: Patients who remained on a phenylalanine-restricted diet accounted for 38% of the cohort. Forty-seven percent of patients discontinued their phenylalanine-restricted diet between 15 and 25 years of age. Of these, 73% remained off diet and 27% restarted a restricted diet at a mean 30 years of age. Fifteen percent of the cohort had untreated PKU. Eleven percent of patients who remained on a phenylalanine-restricted diet for 36 years received the optimum amount of prescribed amino acid supplements. Patients had a mean 12 GP visits per year and 1 hospital outpatient visit annually, but phenylalanine levels were only measured once every 18 to 24 months. The mean NHS cost (at 2007/08 prices) of managing a PKU sufferer over the first 36 years of their life was estimated to range between £21,000 and £149,000, depending on the amount of prescribed nutrition they received.

Conclusion: The findings suggest that the majority of patients with PKU were under-treated.. The NHS cost of patient management should not be an obstacle to encouraging patients to remain on a restricted diet until further information becomes available about the long-term clinical impact of stopping such a diet. Nevertheless, patients require counselling and managed follow-up regardless of the choices they make about their diet.